BlackRock Amends Edgewise Therapeutics Stake (SC 13G/A)
Ticker: EWTX · Form: SC 13G/A · Filed: Feb 7, 2024 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | SC 13G/A |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Edgewise Therapeutics stake, signaling continued institutional interest.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on February 7, 2024, indicating a change in its ownership of Edgewise Therapeutics, Inc. common stock as of January 31, 2024. This filing updates BlackRock's previous disclosure, showing their continued significant, but passive, investment in the pharmaceutical company. For investors, this means a major institutional player like BlackRock still sees value in Edgewise Therapeutics, which can be a positive signal, but the specific change in their holding percentage isn't detailed in the provided snippet, so the exact impact is unclear without further data.
Why It Matters
This filing shows BlackRock, a major institutional investor, continues to hold a significant stake in Edgewise Therapeutics, signaling their ongoing confidence in the company's prospects.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.
Analyst Insight
An investor should note BlackRock's continued, passive institutional ownership in Edgewise Therapeutics, but recognize this filing alone doesn't provide specific details on the change in their holding percentage or a strong buy/sell signal.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Edgewise Therapeutics, Inc. (company) — the subject company whose stock is being reported
- January 31, 2024 (date) — the date of the event requiring the filing
- February 7, 2024 (date) — the filing date of the SC 13G/A
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., identified by CIK 0001364742.
What is the subject company whose securities are being reported?
The subject company is Edgewise Therapeutics, Inc., identified by CIK 0001710072.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was January 31, 2024.
What is the CUSIP number for the class of securities reported?
The CUSIP number for the Common Stock of Edgewise Therapeutics Inc. is 28036F105.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 7, 2024 regarding Edgewise Therapeutics, Inc. (EWTX).